Machine learning reveals potential COVID-19 therapeutic compounds
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
List view / Grid view
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
As more of the small devices in the lab become connected, more laboratory workflows will be observable, and variability will be better understood.
Learn how one lab is saving time, improving traceability, and standardising protocols by using connected tools and recording all workflows digitally.
Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research.
Neuroinflammation study by combining human iPSC-derived astrocytes and HTRF.
Get reproducible and quantitative count, size, morphology and particle ID in one system with the Aura™.
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.